A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy ...

Credit: Daiichi Sankyo. Vanflyta is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved Vanflyta ® (quizartinib) in combination with standard cytarabine ...

Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated ...

VANFLYTA is the first and only FLT3 inhibitor to be approved by the FDA specifically for FLT3-ITD positive AML and across the three phases of treatment – induction, consolidation and maintenance in ...

Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult ...

Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL) No significant financial relationships ...

Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health ...

Factors associated with occurrence of acute leukemias and myelodyplastic neoplasms as seen at the Kenyatta National Hospital, Nairobi, Kenya. Real-world adherence and tolerability of FLT3 inhibitors ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy ...